Kornimate/medical-research-clean huggingface dataset:
craniocervical dysfunction index in patients with temporomandibular joint dysfunction

Conditions: Temporomandibular Joint Dysfunction; Craniocervical Dysfunction; Reliability; Validity

Summary: the aims of this study were to perform cultural adaptation of the craniocervical dysfunction index in patients with temporomandibular joint dysfunction, reliability and validity of the index turkish speaking adults.


Eligibility criteria:
inclusion criteria: * between the ages of 20-60 years * clinical diagnosis of non-specific neck pain * being able to communicate in turkish * volunteering to participate in the study exclusion criteria: * over 60 years of age * those with impairments in cervical mobility that affected the postural assessment
a registry study of shujinjianyao pill used in clinical real world

Conditions: Sciatica

Summary: the purpose of this study is to get to know how shujinjianyao pill in hospital results in drug-induced liver injury or other adverse drug reactions from a cohort event monitoring as registration research.

in order to monitor drug-induced liver injury or other adverse drug reactions of shujinjianyao pill in clinical real world, registry study is a suitable method in this area. meanwhile, the investigators will use nested case-control study to find out the mechanism of drug-induced liver injury. calculate the incidence of drug-induced liver injury or other adverse drug reactions is one of the main aims for this study. therefore, safety monitoring of shujinjianyao pill is an very important problem that needs to be done through a large sample observational study. according to the relevant regulations of the state drug administration(sda), 3000 cases need to be registered at least. the aim population is who use shujinjianyao pill with normal liver function before medication from june 2018 to october 2019.

Eligibility criteria:
inclusion criteria: * 1.patients with normal liver function before medication. * 2.patients suffered from waist and knee pain or sciatica. exclusion criteria: * 1.patients who are pregnant, phrenetic, and suffered from serious illness. * 2.patients suffered from viral hepatitis or autoimmune hepatitis or alcoholic hepatitis or hereditary metabolic hepatitis or cirrhosis or cancer of the liver.

Keywords: waist and knee pain sciatica
neuropsychological rehabilitation of spontaneous confabulation: a replica study

Conditions: Memory Disorders

Summary: confabulators consistently generate false memories without intention to deceive and with great feeling of rightness. however, there is currently no known effective treatment for them. in order to fill this gap, we performed a neuropsychological treatment in two groups of confabulators: experimental vs. control (clinicaltrials.gov id: nct02540772). now, we intend to replicate the treatment with a larger sample of confabulators and with other two control groups: non-confabulator patients with brain injury and healthy individuals

the treatment consisted of some brief material that patients had to learn and recall at both immediate and delayed moments. after both recollections, patients were given feedback about their performance (errors and correct responses). pre-treatment and post-treatment measurements were administered. non-confabulator patients and healthy participants performed only the pre-treatment measurement.

Eligibility criteria:
inclusion criteria: * the presence of spontaneous confabulations after acute brain injury, for at least three months and without clinical improvement (interfering with the patient's daily life with frequent arguments and exhaustive supervision). * the presence of momentary confabulations in the spanish adaptation of dalla barba provoked confabulation interview. * prior to injury, all patients should be completely independent for daily living. exclusion criteria: * the presence of impairment in alertness. * dementia. * acute confusional state. * a history of drug abuse. * psychiatric antecedents.

Keywords: confabulations neuropsychological rehabilitation memory
phase 2 trials of na-931 to study subjects who are obese with at least one weight-related comorbid condition

Conditions: Weight Loss; Obesity; Body Weight; Body Weight Changes

Summary: this is a phase 2 randomized, double-blind, placebo-controlled, parallel arm study of na-931 in adults who are obese (bmi ≥30 kg/m2) or who are overweight (bmi ≥27 kg/m2) with at least one weight-related co-morbid condition.

this is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of na-931 in adults who are obese (bmi ≥30 kg/m2) or who are overweight (bmi ≥27 kg/m2) with at least one weight-related co-morbid condition.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years of age at the time of signing the informed consent 2. body mass index (bmi) ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and bmi \<50 kg/m2 exclusion criteria: 1. history of or current clinically significant medical or psychiatric disorder that, in the opinion of the investigator, does not support study participation 2. self-reported body weight change of 5% or more within 3 months of screening 3. current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational) 4. current or past diagnosis of chronic pancreatitis 5. calcitonin ≥20 ng/l measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened) 6. any glucagon-like peptide 1 (glp-1) receptor agonist or glp-1/ glucose-dependent insulinotropic polypeptide (gip) dual agonist within 6 months of screening 7. any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Keywords: obesity overweight weight loss
respimat® combivent trial in chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the respimat® inhaler (20 mcg), and combivent® mdi administered q.i.d on fev1 at intervals over a treatment period of 12 weeks in patients with copd. specifically, non-inferiority of combivent respimat® to combivent® mdi in fev1 auc from 0 to 6 hours , superiority of combivent respimat® to atrovent respimat® monotherapy in fev1 auc from 0 to 4 hours, and non-inferiority of combivent respimat® to atrovent respimat® monotherapy in fev1 auc from 4 to 6 hours will be analyzed. in addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.


Eligibility criteria:
inclusion criteria: outpatients of either sex, 40 years or older, with a diagnosis of copd (fev1 65% predicted normal and fev1/fvc 70%). exclusion criteria: patients with significant diseases other than copd that may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study, with a history of asthma or allergic rhinitis, who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy or using oral corticosteroid me dication at unstable doses (i.e., less than 6 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day will be excluded.
induction chemotherapy combined with toripalimab in locoregionally-advanced laryngo-hypopharyngeal squamous cell cancer

Conditions: Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer

Summary: this is a non-randomized phase 1, open-labeled clinical study, 1-arm, single center, to observe efficacy and safety of chemotherapy plus pd-l1 antibody toripalimab every 21 days for 2 cycles as induction regimen in locoregionally-advanced laryngo-hypopharyngeal squamous cell cancer patients.

locoregionally advanced laryngo-hypopharyngeal squamous cell cancer patients have the demand of laryngo-preservation. induction chemotherapy (fp) combined with toripalimab (a humanized igg4 monoclonal antibody against pd-1) will be given. this regimen will be given every 21 days for 2 cycles. radiological examinations and pet(fdg/fapi) examinations pre/post-treatment will be administrated for response evaluation.

Eligibility criteria:
inclusion criteria: 1. male/female patients aged≥18 years. 2. histologically confirmed laryngo-hypopharyngeal squamous cell cancer, previously untreated (including surgery/radiotherapy/chemotherapy/immunotherapy). 3. locoregionally-advanced disease stage ct2-4n0-3m0. 4. ecog performance status 0 to 1. 5. adequate organ function: absolute neutrophil count (anc) ≥1.5x109/l, white blood count ≥3.5x109/l, platelets ≥75x109/l, hemoglobin (hb) ≥70g/l, alt/ast ≤2.5x uln (for patient with liver metastasis alt/ast ≤5x uln), serum bilirubin ≤1.5x uln, serum creatinine ≤1.5x uln. 6. hbv infected patients (inactive/asymptomatic carrier, chronic or active) with hbv dna\<500iu/ml (or 2500 copies/ml). 7. pregnancy test of female patients with fertile activity should be negative within 7 days before enrollment. patients should keep contraception during treatment. 8. willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans with informed consent form. exclusion criteria: 1. pregnancy or children bearing potential. 2. metastasis. 3. received prior therapy with an anti-pd-1, anti-pd-l1, or anti-pd-l2 agent. 4. have other malignant tumors within 5 years, except for fully treated basal cell/squamous cell skin cancer/cervical cancer 5. uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above nyha ii, unstable angina, myocardial infarction within 6 months; 6. with uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (\>10mg/d prednisone). 7. with uncontrollable complications 8. inadequate organ function 9. known hypersensitivity reaction to any of the study drugs or components. 10. other unsuitable conditions determined by investigators.
ongoing registry of deep venous reconstructions

Conditions: Venous Thrombosis

Summary: ongoing registration of deep venous obstructive disease patients treated by means of percutaneous transluminal angioplasty (pta) and stenting with or without endophlebectomy (surgical desobstruction, also termed endovenectomy) of the common femoral vein and/or arteriovenous fistula creation.

literature has shown endovenous reconstructions to be safe en effective in treating deep venous obstructive disease. deep venous obstruction can develop in cases of (iliac) vein compression syndromes (e.g. may-thurner syndrome) or in cases of post-thrombotic syndrome. in patients with both significant complaints (objectively measured) and venous obstruction objectified on imaging (duplex ultrasonography, magnetic resonance venography, ct-venography) stenting is indicated. in cases of extensive post-thrombotic damage to the veins of the lower extremity endophlebectomy (surgical desobstruction) of the common femoral vein can be warranted. this operation is generally combined with the creation of an arteriovenous fistula. data of patients treated in our tertiary medical centre are entered in a prospective digital database, and continuously updated.

Eligibility criteria:
inclusion criteria: * venous obstruction/occlusion in the femoral vein, common femoral vein, external iliac vein, common iliac vein or inferior vena cava exclusion criteria: * intolerance to anticoagulant medication * a life expectancy \<1 year

Keywords: stent angioplasty endophlebectomy
three dimensional ultrasonographic detection of human ovulation

Conditions: Ovulation Disorder

Summary: the research aims to compare diagnosis of ovulation and anovulation in 2d and 3d ultrasonography.

thirty healthy participants will be enrolled. when their dominant ovarian follicle has a diameter of 16 mm or more, an anti-prostaglandin medication, indomethacin 30 mg, will be administered three times daily for 1-7 days. anti-prostaglandins are known to cause anovulation. daily 2d and 3d ultrasound scans, and urine and finger prick blood tests for reproductive hormonal assays will be performed. the medication will be discontinued once ultrasound features of anovulation are observed. these study procedures will also be carried out on days 1, 3 and 7 after anovulation. a second cohort of 30 participants who had 2d and 3d ultrasound scans and hormonal assays in a natural cycle in a previous study (bio 2080; nct05531357) will also be evaluated. these two groups represent the anovulatory and ovulatory groups, respectively, and their 2d and 3d ultrasound features will be compared. with 2d ultrasonography as a gold standard, the study aims to determine if 3d ultrasonography improves ovulation assessment and improves the recognition of anovulatory follicles in infertility treatment

Eligibility criteria:
inclusion criteria: * healthy biological females * regular menstrual cycles (21-35 days) exclusion criteria: * bmi \ 30 * pregnancy * breastfeeding mothers * history of infertility * history of hysterectomy or oophorectomy * reproductive health issues that can interfere with study outcomes * smoking * not on any hormonal medication that affects reproduction (including hormonal contraception) * history of metabolic syndrome or untreated thyroid disease * contra-indication to non-steroidal anti-inflammatory drug (nsaid) use. these include: * gastric ulcers or gastro-intestinal bleeding * history of myocardial infarction or a coronary artery bypass * cerebrovascular disease * hypertension * chronic or acute renal failure * severe liver disease * nasal polyp syndrome

Keywords: ovulation 3d ultrasonography
edwards intuity valve system cadence study

Conditions: Aortic Valve Disease; Aortic Stenosis

Summary: the study purpose is to compare the edwards intuity valve system with commercially available stented aortic bioprostheses, in patients requiring aortic valve replacement surgery with coronary artery bypass.

this is a randomized study comparing the cross-clamp time (xct) and cardiopulmonary bypass time (cpbt) of the edwards intuity valve system with any commercially available stented aortic bioprosthesis, in patients with logistic euroscore 1 ≥ 6 undergoing elective surgical aortic valve replacement surgery with concomitant coronary bypass grafts. additionally, the aim is to gather sufficient data to quantify the effect size of short term patient benefit outcomes previously identified from literature and finally to explore additional healthcare resource utilization or health economic endpoints.

Eligibility criteria:
inclusion: * ≥18 years of age * aortic stenosis / mixed aortic stenosis and aortic insufficiency * savr+cabg (1-4 distal anastomoses) * log. euroscore ≥6 * nyha class ≥ii exclusion (i.a.): * pure aortic insufficiency * pre-existing prosthetic heart valve or ring * congenital true bicuspid / unicuspid aortic valve * lvef \<20%

Keywords: aortic valve replacement aortic stenosis edwards intuity
family empathic behaviour versus nurse empathic behaviour

Conditions: Cardiovascular Disease

Summary: the objective was to compare the frequency and intensity of symptoms of anxiety in patients of preoperative cardiac surgery who received empathic behaviour from nurse or family or those who received no specific type of empathic behaviour. this is a randomized clinical trial. the sample consisted of 66 patients in preoperative of cardiac surgery, who were divided in three groups: empathic behaviour by nurses, without specific empathic behaviour and by family. anxiety was assessed at two time points: before and after the intervention. the instrument used was developed and validated, comprising 19 defining characteristics of the nursing diagnosis anxiety. the hypothesis is that the group who received empathic behaviour from nurse or family will reduce the anxiety.

primary outcome is anxiety. anxiety was assessed by a nurse using of an instrument developed and validated previous, based on 19 defining characteristics described by nanda-international for the nursing diagnosis anxiety: verbalization of fear (expressed concern); apprehension, nervousness, tension, restlessness, anxiety, anxious, insomnia, abnormal respiratory rate, increased pulse, dry mouth, increased perspiration, fatigue, cranky; voice / ends trembling, chest / abdominal pain, urinary urgency, nausea, and vomiting. patients were evaluated for the presence and absence of these anxiety symptoms through scores: 0 (no symptom) and 1 (presence of symptom). for analysis of the results was carried out the sum of the scores of each symptom, ranging from 0 to 21, with the higher the score, the greater was the anxiety symptoms presented by the patient.

Eligibility criteria:
inclusion criteria: * patients older than 18 years; * literate; * patient who agreed to participate in the study by signing the consent form at least 24 hours prior to surgery. exclusion criteria: * patients with a history of surgery; * patients in preoperative cardiac transplantation; * patients who did not have at least two defining characteristics of the nursing diagnosis anxiety; * patients using anxiolytics; * smokers and / or patients who drank any amount of alcohol daily.
effects of lower limb resistance band exercises in phase 1 cardiac rehabilitation

Conditions: Cardiovascular Diseases

Summary: this study will be randomized controlled trial with non-probability purposive sampling. study conducted among post cabg patients. sample size will be 56, 28 in each group. outcome will be measured by using 6 minute walk test, spirometry (fvc, fev1/fvc and pef), functional independence measure.

this study will be randomized controlled trial with non-probability purposive sampling. study conducted among post cabg patients. descriptive analysis will be applied. data will be collected from rehmatul lil alameen institute of cardiology lahore. sample size will be 56, 28 in each group. in addition to the routine phase 1 cardiac rehabilitation for experimental group the exercise protocol consisted of 10 minutes of warm up, elastic band strength exercise protocol (30 minutes) and cool down (5 minutes) so that an exercise session lasted about 45-50 minutes, exercise will performed circularly 2 sets, 10 repetition with a 2 minute rest after each cycle and monitored the performance of exercise for 6 days. resisted band exercise are extending thighs, closing thighs, opening thighs, bending thighs, dorsiflexion, plantarflexion. for control group routine phase 1 cardiac rehabilitation only. outcome will be measured by using 6 minute walk test, spirometry (fvc, fev1/fvc and pef), functional independence measure.

Eligibility criteria:
inclusion criteria: * age 35 to 60 * female and male both * hemodynamic stable patients * arrhythmias or angina not present * post elective sternotomy surgery * post extubating exclusion criteria: * chronic obstructive pulmonary disease * neurological sequelae * neuromuscular disease * emergency or off pump surgery * surgical re-intervention * patient who remained on mechanical ventilation longer than 24 hours * patient who had a baseline partial pressure of oxygen (pao2) less than 75 mmhg and partial pressure of carbon dioxide (pco2) 45 mmhg * patients who had history of respiratory tract infection within a period of three months

Keywords: coronary artery bypass grafting cardiac rehabilitation resistance band exercise
construction and validation of dementia care management competency

Conditions: Dementia

Summary: this study will use the concept of competency-based education to develop an innovative integrated curriculum with epas to guide learning and assessment of competency performance to equip students with dementia care management competency and cultivate professionals to meet the social trends and practical needs.

this study will use the concept of competency-based education to develop an innovative integrated curriculum with epas to guide learning and assessment of competency performance to equip students with dementia care management competency and cultivate professionals to meet the social trends and practical needs. the first year is a preparation period for the development of the project, which focuses on developing research tools and teacher empowerment, and evaluating the effectiveness of the control group in implementing conventional teaching methods. the second year is the program testing, implementation and evaluation period, in which two phases of the intervention is conducted and the post-intervention phase of competency is evaluated. this study is expected to establish a competency-based innovative and integrated curriculum for dementia care management over a two-year period. the results of the study will be used as a reference for schools or practices in the development of competency-based curriculum integration.

Eligibility criteria:
inclusion criteria: * (1)be at least 20 years old. (2)the students are freshmen majoring in the department of gerontology and health care management, and taking the course on dementia care. (3)before taking the course on dementia care, have taken courses on basic geriatric nursing. (4)voluntary participation exclusion criteria: * the students who suspension of schooling.

Keywords: teaching method medical practice management competence competency-based education